LMNL - Liminal Biosciences closes sale of plasma-derived therapeutics manufacturing facility

Liminal BioSciences (LMNL) has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion.The company received a consideration of $5M upon deal closure.Liminal will also be entitled to receive 70% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") by its subsidiary, Prometic Biotherapeutics.Shares up more than 6% post market.

For further details see:

Liminal Biosciences closes sale of plasma-derived therapeutics manufacturing facility